| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,833 |
8,147 |
$540K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,249 |
2,654 |
$210K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,949 |
2,433 |
$187K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,471 |
3,339 |
$138K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
1,064 |
887 |
$111K |
| 99199 |
Unlisted special service, procedure or report |
10,233 |
5,867 |
$65K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
459 |
355 |
$39K |
| 99406 |
|
5,187 |
3,802 |
$37K |
| 81025 |
|
3,342 |
2,498 |
$21K |
| 99401 |
|
865 |
634 |
$20K |
| 83970 |
|
394 |
320 |
$17K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,399 |
952 |
$14K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
428 |
349 |
$13K |
| 80053 |
Comprehensive metabolic panel |
1,030 |
823 |
$9K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,060 |
836 |
$8K |
| 36415 |
Collection of venous blood by venipuncture |
3,988 |
2,973 |
$6K |
| 93000 |
|
533 |
414 |
$5K |
| 94375 |
|
336 |
255 |
$5K |
| 72100 |
|
341 |
242 |
$5K |
| 84480 |
|
308 |
242 |
$4K |
| 80061 |
Lipid panel |
335 |
271 |
$4K |
| 86769 |
|
92 |
89 |
$4K |
| 84439 |
|
388 |
312 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
126 |
67 |
$3K |
| 82607 |
|
215 |
168 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
352 |
290 |
$3K |
| 84443 |
Thyroid stimulating hormone (TSH) |
164 |
148 |
$3K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
46 |
40 |
$3K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
48 |
38 |
$2K |
| 99443 |
|
42 |
27 |
$2K |
| 82728 |
|
145 |
120 |
$2K |
| 72050 |
|
123 |
81 |
$2K |
| 82746 |
|
110 |
90 |
$2K |
| 86703 |
|
137 |
107 |
$2K |
| 83550 |
|
160 |
131 |
$1K |
| 72070 |
|
109 |
70 |
$1K |
| 99442 |
|
29 |
14 |
$996.78 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
342 |
255 |
$977.55 |
| 90756 |
|
109 |
76 |
$926.77 |
| 83540 |
|
118 |
95 |
$797.53 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
116 |
92 |
$725.57 |
| 80050 |
General health panel |
78 |
69 |
$716.94 |
| 81002 |
|
540 |
383 |
$651.36 |
| 86431 |
|
89 |
68 |
$513.09 |
| 82962 |
|
330 |
238 |
$493.28 |
| 84550 |
|
92 |
71 |
$415.42 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
702 |
532 |
$238.07 |
| 83735 |
|
28 |
26 |
$214.76 |
| 87905 |
|
15 |
12 |
$209.46 |
| 90688 |
|
17 |
14 |
$178.50 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
86 |
71 |
$77.70 |
| 3074F |
|
5,652 |
4,394 |
$50.00 |
| 3008F |
|
10,399 |
7,995 |
$50.00 |
| 82044 |
|
12 |
12 |
$28.24 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
68 |
60 |
$25.09 |
| G0446 |
Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes |
36 |
31 |
$25.05 |
| 3079F |
|
2,245 |
1,819 |
$25.00 |
| 3078F |
|
5,326 |
4,151 |
$25.00 |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
38 |
33 |
$17.66 |
| 3075F |
|
1,120 |
921 |
$0.00 |
| 3044F |
|
783 |
603 |
$0.00 |
| 1125F |
|
51 |
46 |
$0.00 |
| 3080F |
|
190 |
167 |
$0.00 |
| 3048F |
|
89 |
76 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
36 |
31 |
$0.00 |
| 1170F |
|
18 |
16 |
$0.00 |
| 4004F |
|
1,206 |
951 |
$0.00 |
| 1159F |
|
762 |
586 |
$0.00 |
| 3077F |
|
748 |
600 |
$0.00 |